Dorsey Wright & Associates’s Regenxbio RGNX Stock Holding History

Dorsey Wright & Associates’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-415	Closed	-$31K	–	333
2018 Q3	$31K	Buy	+415	New	+$29.9K	0.01%	131

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dorsey Wright & Associates's RGNX Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 415 shares — an estimated $31K sold.

Dorsey Wright & Associates first reported a position in RGNX in Q3 2018 and held it in 1 quarter. The position peaked at $31K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

Dorsey Wright & Associates reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
Dorsey Wright & Associates sold 415 Regenxbio shares in Q4 2018, an estimated $31K.
Dorsey Wright & Associates first reported a position in Regenxbio in Q3 2018 and held it in 1 quarter.
Dorsey Wright & Associates's Regenxbio position peaked at $31K in Q3 2018.
183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.